Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

History

Disabled Children

Endothelium, Vascular

Phosphotransferases (A

Safety and Activity of

Staphylococcus aureus

See All (5) pages

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Diarrhea
Disease-Free Survival
Drug Resistance, Neoplasm
Fallopian Tube Neoplasms
Fatigue
Female
Folate Receptor 1
Humans
Hypotension
Immunoconjugates
Maytansine
Middle Aged
Nausea
Ovarian Neoplasms
Peritoneal Neoplasms
Platinum Compounds
Retreatment
Vision Disorders

authors with profiles

Michael Birrer